Last reviewed · How we verify
NCT07307430
Effect of Narrative Education on Glycemic Control in Adults With Type 2 Diabetes in Primary Care
NA trial testing Structured Narrative Education Program in Type 2 Diabetes Mellitus (T2DM) in 226 participants. Not yet recruiting.
15 November 2026
Quick facts
| Lead sponsor | Mustafa Kemal University |
|---|---|
| Phase | NA |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 226 |
| Start date | 15 February 2026 |
| Primary completion | 15 November 2026 |
| Estimated completion | 15 November 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Structured Narrative Education Program
Conditions studied
- Type 2 Diabetes Mellitus (T2DM) — all drugs for Type 2 Diabetes Mellitus (T2DM) →
- Diabetes Self-management — all drugs for Diabetes Self-management →
- Diabetes Education — all drugs for Diabetes Education →
Sponsor
Mustafa Kemal University
Who can join
18 and older, any sex, with Type 2 Diabetes Mellitus (T2DM) or Diabetes Self-management. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Type 2 diabetes is common in primary care, and daily self-care behaviors are essential for achieving blood sugar targets. This randomized, two-arm clinical trial will evaluate whether a structured narrative education program added to usual diabetes care improves glycemic control compared with usual care alone in adults with type 2 diabetes. Eligible participants (age ≥18 years) with suboptimal glycemic control (HbA1c ≥7.0% in the last 3 months) will be randomized 1:1 to either standard care or standard care plus narrative education. The narrative education program will be delivered by a family physician over 3 months and includes two individual face-to-face sessions (approximately 20-30 minutes) at Day 0 and Day 15 and four brief telephone reinforcement calls (approximately 3-5 minutes) on Days 30, 45, 60, and 75. The primary outcome is the absolute change in HbA1c from baseline (Day 0) to Day 90. Secondary outcomes include changes in diabetes self-care activities (SDSCA-TR), diabetes-related distress (PAID-5-TR), and body mass index (BMI) from Day 0 to Day 90.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07307430
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Type 2 Diabetes Mellitus (T2DM)
Currently open trials in the same condition.
- NCT07533539 — Phase I Study to Evaluate the Pharmacokinetics and Safety After Co-administration of L03RD1 and L03RD2 or Administration · Phase 1 · recruiting
- NCT07366775 — A Telenursing Program to Support Diabetes Self-Management · NA · active not recruiting
- NCT07398495 — Multimodal Training Effects in Middle-Aged and Older Adults With Diabetic Sarcopenia · NA · recruiting
- NCT07465224 — A Study to Evaluate ALN-4324 on Insulin Sensitivity in Adults With Type 2 Diabetes Mellitus · Phase 2 · recruiting
- NCT07442006 — Glycemic Variability of Combination Therapies in T2DM · Phase 4 · recruiting
Other Mustafa Kemal University trials
Trials by the same sponsor.
- NCT05969652 — Comparison of the Effectiveness Heavy Slow Resistance and Eccentric Training in Rotator Cuff Tendinopathy · NA · not yet recruiting
- NCT07328685 — Basic Body Awareness Therapy in Individuals With Migraine · NA · not yet recruiting
- NCT06715397 — Cross-Cultural Adaptation, Validity and Reliability of the Turkish Version of the Adolfsson-Björnsson Upper Extremity Ac · enrolling by invitation
- NCT07375576 — Outcomes of Pulpotomy and Root Canal Treatment in Teeth With Symptomatic Irreversible Pulpitis · NA · recruiting
- NCT07237620 — The Effect of Different Intracanal Medicaments on Periapical Lesion Healing · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07307430 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mustafa Kemal University
- Last refreshed: 31 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07307430.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing